Medicortex Finland Oy (www.medicortex.fi), a biotechnology company developing a diagnostic kit for brain injury based on a medical breakthrough biomarker, recently was granted clearance to begin a clinical trial. The trial will consist of patients that are hospitalized due to a head injury.
“Collecting and testing human samples in a clinical trial is a significant accomplishment for Medicortex, and represents a meaningful step forward in the development of a fast inexpensive diagnostic kit for head injury,” said Dr. Adrian Harel, Chairman and Chief Executive Officer of Medicortex Finland. “Brain injury is a devastating condition with mortality if not diagnosed. The opportunity to develop the first portable non-invasive kit for head injury and concussion to help the patients and families that so desperately need it is remarkable.”
Samples of body fluids: blood, urine, plasma and Cerebrospinal fluid will be taken from these subjects and will be analyzed for a novel biomarker using a biochemical assay from Medicortex.
In this clinical trial. Medicortex intends to collect body fluid samples of 12 patients who have sustained a head injury, and analyze for the existence of a biomarker between the patients and healthy control subjects. Based on our earlier laboratory animal tests we can expect promising result from the study.
“We are excited to begin a clinical test, confirming the presence of this unique biomarker, it will be further developed into a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications, ” said Dr. Marten Kvist, a TBI expert.
Medicortex is working towards the identification of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals, and also by people with no medical profession.
This clinical trial is supported and funded in part by Tekes (the Finnish Funding Agency for Innovation).
Medicortex Finland Oy is a biotechnology company dedicated to developing diagnostics and treatments for acute neurodegenerative conditions, including brain injury and concussion. One of the company’s missions is to identify a new biomarker in order to reliably assess the severity and extent of brain injury. Medicortex was founded by Dr. Adrian Harel in Turku, Finland, in 2014 and it operates as a privately owned company. Dr. Harel has a track record in the business management and leadership of early-stage biotechnology companies.